Mesoblast Limited (MSB) - Financial and Strategic SWOT Analysis Review

Date: August 30, 2016
Pages: 53
Price:
US$ 300.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M79A7626DDCEN
Leaflet:

Download PDF Leaflet

Mesoblast Limited (MSB) - Financial and Strategic SWOT Analysis Review
Mesoblast Limited (MSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Mesoblast Limited (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft versus host disease; MPC-06-ID, for the treatment of chronic low back pain (CLBP); and MPC-300-IV for the treatment of chronic inflammatory conditions such as biologic-refractory rheumatoid arthritis, and diabetic nephropathy. Mesoblast conducts clinical trials in various areas such as cardiac diseases, spinal orthopedic disorders, cancer, hematological conditions, and immune-mediated and inflammatory conditions. The company has operational presence in the US and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Mesoblast Limited Key Recent Developments

Aug 25, 2016: Mesoblast Reports Financial Results And Operational Highlights For The Three Months And For The Year Ended 30 June 2016
Aug 17, 2016: Mesoblast Strengthens Key United States Patent Portfolio For the Treatment Of Rheumatic Diseases
May 20, 2016: Mesoblast Receives $6.2 Million From Australian Government For Research And Development Activities
May 09, 2016: Mesoblast Reports Financial Results For Period Ended 31 March 2016 And Provides Corporate Update
Mar 24, 2016: Key United States Patent Granted For Cell-Based Treatment Of Rheumatoid Arthritis And Other Rheumatic Conditions

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Mesoblast Limited - Key Facts
Mesoblast Limited - Key Employees
Mesoblast Limited - Key Employee Biographies
Mesoblast Limited - Major Products and Services
Mesoblast Limited - Pharmaceutical Pipeline Products Data
Mesoblast Limited, Pipeline Products by Therapy Area
Mesoblast Limited, Pipeline Products by Development Phase
Mesoblast Limited - History
Mesoblast Limited - Company Statement
Mesoblast Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Mesoblast Limited - Business Description
Mesoblast Limited - Corporate Strategy
Mesoblast Limited - SWOT Analysis
SWOT Analysis - Overview
Mesoblast Limited - Strengths
Strength - Focused Research and Development Activities
Strength - Strong Collaborations
Strength - Proprietary Technology
Mesoblast Limited - Weaknesses
Weakness - High Costs
Mesoblast Limited - Opportunities
Opportunity - Agreement with Celgene Corporation
Opportunity - Changing Demographics
Opportunity - Increasing Healthcare Expenditure in the US
Mesoblast Limited - Threats
Threat - Uncertain R&D Outcomes
Threat - Competitive Pressures
Threat - Stringent Government Regulations
Mesoblast Limited - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Mesoblast Limited, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 25, 2016: Mesoblast Reports Financial Results And Operational Highlights For The Three Months And For The Year Ended 30 June 2016
Aug 17, 2016: Mesoblast Strengthens Key United States Patent Portfolio For the Treatment Of Rheumatic Diseases
May 20, 2016: Mesoblast Receives $6.2 Million From Australian Government For Research And Development Activities
May 09, 2016: Mesoblast Reports Financial Results For Period Ended 31 March 2016 And Provides Corporate Update
Mar 24, 2016: Key United States Patent Granted For Cell-Based Treatment Of Rheumatoid Arthritis And Other Rheumatic Conditions
Feb 16, 2016: Mesoblast Reports on First Half and Second Quarter Financial Results
Dec 16, 2015: Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results
Nov 23, 2015: Mesoblast Investor Update
Nov 15, 2015: Mesoblast Lists On Nasdaq
Oct 27, 2015: Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Mesoblast Limited, Key Facts
Mesoblast Limited, Key Employees
Mesoblast Limited, Key Employee Biographies
Mesoblast Limited, Major Products and Services
Mesoblast Limited, Number of Pipeline Products by Therapy Area
Mesoblast Limited, Number of Pipeline Products by Development Stage
Mesoblast Limited, Pipeline Products By Therapy Area and Development Phase
Mesoblast Limited, History
Mesoblast Limited, Subsidiaries
Mesoblast Limited, Key Competitors
Mesoblast Limited, Annual Ratios
Mesoblast Limited, Interim Ratios
Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Mesoblast Limited, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Mesoblast Limited, Pipeline Products by Therapy Area
Mesoblast Limited, Pipeline Products by Development Phase
Mesoblast Limited, Performance Chart (2012 - 2016)
Mesoblast Limited, Ratio Charts
Mesoblast Limited, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Mesoblast Limited, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

CSL Limited
Bone Medical Limited
Alchemia Limited
Actinogen Limited
Acrux Limited
Skip to top


Ask Your Question

Mesoblast Limited (MSB) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: